InhaleRx Limited (IRX.AX)
AUD 0.04
(0.0%)
AUD 0.04
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.59 Million AUD | 32.95% |
| 2022 | 1.94 Million AUD | 65.41% |
| 2021 | 1.17 Million AUD | 18.42% |
| 2020 | 994.77 Thousand AUD | -53.72% |
| 2019 | 2.14 Million AUD | -7.86% |
| 2018 | 2.33 Million AUD | -10.61% |
| 2017 | 2.6 Million AUD | 647.36% |
| 2016 | 349.21 Thousand AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 378.94 Thousand AUD | -51.48% |
| 2024 Q2 | 378.94 Thousand AUD | 0.0% |
| 2023 Q2 | 1.84 Million AUD | 98.52% |
| 2023 Q1 | 930.11 Thousand AUD | -11.23% |
| 2023 FY | 2.62 Million AUD | 34.85% |
| 2023 Q4 | 781.01 Thousand AUD | 100.0% |
| 2023 Q3 | 390.5 Thousand AUD | -78.85% |
| 2022 FY | 1.94 Million AUD | 65.41% |
| 2022 Q4 | 1.04 Million AUD | 102.11% |
| 2022 Q2 | 930.56 Thousand AUD | 99.89% |
| 2022 Q1 | 465.54 Thousand AUD | -3.74% |
| 2022 Q3 | 518.44 Thousand AUD | -44.29% |
| 2021 FY | 1.17 Million AUD | 18.42% |
| 2021 Q4 | 483.61 Thousand AUD | 56.76% |
| 2021 Q1 | 280.47 Thousand AUD | -48.64% |
| 2021 Q2 | 555.36 Thousand AUD | 98.01% |
| 2021 Q3 | 308.51 Thousand AUD | -44.45% |
| 2020 FY | 994.77 Thousand AUD | -53.72% |
| 2020 Q4 | 546.07 Thousand AUD | 85.31% |
| 2020 Q1 | 234.68 Thousand AUD | -61.24% |
| 2020 Q2 | 441.42 Thousand AUD | 88.1% |
| 2020 Q3 | 294.67 Thousand AUD | -33.24% |
| 2019 Q2 | 751.48 Thousand AUD | 40.33% |
| 2019 Q1 | 535.49 Thousand AUD | 52.27% |
| 2019 Q3 | 648.57 Thousand AUD | -13.69% |
| 2019 FY | 2.14 Million AUD | -7.86% |
| 2019 Q4 | 605.51 Thousand AUD | -6.64% |
| 2018 Q1 | 637.56 Thousand AUD | -24.84% |
| 2018 FY | 2.33 Million AUD | -10.61% |
| 2018 Q4 | 351.67 Thousand AUD | 0.0% |
| 2018 Q3 | 351.67 Thousand AUD | -44.84% |
| 2018 Q2 | 637.56 Thousand AUD | -0.0% |
| 2017 Q2 | 705.57 Thousand AUD | -0.0% |
| 2017 Q4 | 848.31 Thousand AUD | 0.0% |
| 2017 FY | 2.6 Million AUD | 647.36% |
| 2017 Q1 | 705.57 Thousand AUD | 0.0% |
| 2017 Q3 | 848.31 Thousand AUD | 20.23% |
| 2016 FY | 349.21 Thousand AUD | 0.0% |
| 2016 Q2 | 31.39 Thousand AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| 4DMedical Limited | 31.48 Million AUD | 91.772% |
| Adherium Limited | 267.7 Thousand AUD | -867.689% |
| Aroa Biosurgery Limited | 66.09 Million AUD | 96.081% |
| Atomo Diagnostics Limited | 1.6 Million AUD | -61.303% |
| Anteris Technologies Ltd | 69.14 Million AUD | 96.254% |
| Control Bionics Limited | 9.82 Million AUD | 73.636% |
| CardieX Limited | 16.64 Million AUD | 84.44% |
| Compumedics Limited | 26.88 Million AUD | 90.363% |
| Cochlear Limited | 1.17 Billion AUD | 99.779% |
| CleanSpace Holdings Limited | 11.35 Million AUD | 77.195% |
| Cyclopharm Limited | 13.38 Million AUD | 80.64% |
| EMVision Medical Devices Ltd | 12.83 Million AUD | 79.814% |
| Nova Eye Medical Limited | 23.99 Million AUD | 89.202% |
| HeraMED Limited | 6.78 Million AUD | 61.808% |
| Imricor Medical Systems, Inc. | -1.11 Million AUD | 332.16% |
| ImpediMed Limited | 28.04 Million AUD | 90.762% |
| LBT Innovations Limited | 1.1 Million AUD | -134.014% |
| Micro-X Limited | 18.76 Million AUD | 86.194% |
| Neurotech International Limited | 8.75 Million AUD | 70.408% |
| OncoSil Medical Limited | 12.03 Million AUD | 78.484% |
| PolyNovo Limited | 34.92 Million AUD | 92.582% |
| Respiri Limited | 8.03 Million AUD | 67.759% |
| SomnoMed Limited | 58.97 Million AUD | 95.607% |
| Universal Biosensors, Inc. | 20 Million AUD | 87.047% |
| Uscom Limited | 5.52 Million AUD | 53.07% |
| Visioneering Technologies, Inc. | 9.63 Million AUD | 73.109% |